Melt Amorphisation of Orlistat with Mesoporous Silica Using a Supercritical Carbon Dioxide: Effects of Pressure, Temperature, and Drug Loading Ratio and Comparison with Other Conventional Amorphisation Methods.
dissolution
melt-amorphisation
mesoporous silica
orlistat
supercritical carbon dioxide
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Apr 2020
20 Apr 2020
Historique:
received:
26
03
2020
revised:
14
04
2020
accepted:
18
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
The aim of this work was to develop an amorphous orlistat-loaded mesoporus silica formulation using the melt-amorphisation by supercritical fluid (MA-SCF) and to investigate the effects of pressure and temperature on the pharmaceutical properties of the developed formulation. In addition, the effect of orlistat mass ratio to the mesoporus silica was also evaluated. The carbon dioxide was used as a supercritical fluid, and Neusilin
Identifiants
pubmed: 32326103
pii: pharmaceutics12040377
doi: 10.3390/pharmaceutics12040377
pmc: PMC7238234
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : 2020R1A2C4002166
Organisme : National Research Foundation of Korea
ID : 2019R1F1A1056350
Organisme : National Research Foundation of Korea
ID : University-Centered Labs-2018R1A6A1A03023718
Références
J Pharm Investig. 2018;48(1):3-17
pubmed: 30546918
J Pharm Investig. 2018;48(1):43-60
pubmed: 30546919
Eur J Pharm Sci. 2008 Mar 3;33(3):306-12
pubmed: 18282694
Pharm Res. 2009 Jun;26(6):1456-66
pubmed: 19267186
Int J Nanomedicine. 2018 Nov 05;13:7095-7106
pubmed: 30464461
J Clin Pharmacol. 1995 Nov;35(11):1103-8
pubmed: 8626884
Int J Pharm. 2007 Jan 10;328(2):152-60
pubmed: 16959448
Diabetes Res Clin Pract. 2005 Jan;67(1):78-83
pubmed: 15620437
AAPS PharmSciTech. 2005 Dec 07;6(4):E618-25
pubmed: 16408863
Eur J Pharm Sci. 2006 Mar;27(4):299-310
pubmed: 16388936
Int J Pharm. 2005 Apr 11;293(1-2):155-64
pubmed: 15778053
Drug Dev Ind Pharm. 2009 May;35(5):555-67
pubmed: 19005918
Eur J Pharmacol. 2002 Apr 12;440(2-3):109-17
pubmed: 12007529
Int J Pharm. 2008 May 22;356(1-2):76-81
pubmed: 18294790
Int J Pharm. 2008 Aug 6;360(1-2):213-8
pubmed: 18550302
Int J Pharm. 2018 Mar 1;538(1-2):1-13
pubmed: 29278733
Eur J Pharm Sci. 2001 Jun;13(3):281-6
pubmed: 11384850
Eur J Pharm Biopharm. 2006 Feb;62(2):171-7
pubmed: 16275049
Adv Drug Deliv Rev. 2017 Aug 1;117:25-46
pubmed: 28342786
J Control Release. 2010 Aug 3;145(3):257-63
pubmed: 20450945
Int J Pharm. 2007 Feb 22;331(1):72-83
pubmed: 17030470
J Control Release. 2005 Nov 28;108(2-3):362-74
pubmed: 16169628
Int J Pharm. 2010 Aug 30;396(1-2):149-55
pubmed: 20540997
Int J Pharm. 2008 Dec 8;364(2):176-87
pubmed: 18597957
Eur J Pharm Biopharm. 2008 May;69(1):223-30
pubmed: 18164930
Adv Drug Deliv Rev. 2008 Feb 14;60(3):399-410
pubmed: 17964684
Eur J Pharm Biopharm. 2008 Jun;69(2):454-65
pubmed: 18359211
Int J Nanomedicine. 2012;7:5565-75
pubmed: 23118538
J Nanosci Nanotechnol. 2019 Feb 1;19(2):634-639
pubmed: 30360134
JAMA. 1999 Jan 20;281(3):235-42
pubmed: 9918478